Literatura académica sobre el tema "Muc expression"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Muc expression".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Muc expression"
Kuznetsov, O. E., V. M. Tsyrkunov y S. Sh Kerimova. "Mucin expression in liver cancer". Doklady of the National Academy of Sciences of Belarus 67, n.º 1 (4 de marzo de 2023): 59–65. http://dx.doi.org/10.29235/1561-8323-2023-67-1-59-65.
Texto completoColecchia, Maurizio, Salvatore Lo Vullo, Patrizia Giannatempo, Daniele Raggi, Federica Perrone, Nicola Nicolai, Mario Catanzaro et al. "Frequent expression of androgen receptor (AR) on tumor cells of muscle-invasive (MIUC) and metastatic urothelial carcinoma (mUC): Insights for clinical research." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): e16019-e16019. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16019.
Texto completoShet, Tanuja, Sucheta Valsangar y Suhas Dhende. "Secretory Carcinoma of Breast: Pattern of MUC 2/MUC 4/MUC 6 Expression". Breast Journal 19, n.º 2 (11 de enero de 2013): 222–24. http://dx.doi.org/10.1111/tbj.12085.
Texto completoJiang, Zhipeng, Huashe Wang, Liang Li, Zehui Hou, Wei Liu, Taicheng Zhou, Yingru Li y Shuang Chen. "Analysis of TGCA data reveals genetic and epigenetic changes and biological function of MUC family genes in colorectal cancer". Future Oncology 15, n.º 35 (diciembre de 2019): 4031–43. http://dx.doi.org/10.2217/fon-2019-0363.
Texto completoTreon, Steven P., Joseph A. Mollick, Mitsuyoshi Urashima, Gerrard Teoh, Dharminder Chauhan, Atsushi Ogata, Noopur Raje et al. "Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone". Blood 93, n.º 4 (15 de febrero de 1999): 1287–98. http://dx.doi.org/10.1182/blood.v93.4.1287.
Texto completoTreon, Steven P., Joseph A. Mollick, Mitsuyoshi Urashima, Gerrard Teoh, Dharminder Chauhan, Atsushi Ogata, Noopur Raje et al. "Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone". Blood 93, n.º 4 (15 de febrero de 1999): 1287–98. http://dx.doi.org/10.1182/blood.v93.4.1287.404k14_1287_1298.
Texto completoBraga, V. M., L. F. Pemberton, T. Duhig y S. J. Gendler. "Spatial and temporal expression of an epithelial mucin, Muc-1, during mouse development". Development 115, n.º 2 (1 de junio de 1992): 427–37. http://dx.doi.org/10.1242/dev.115.2.427.
Texto completoBraga, V. M. y S. J. Gendler. "Modulation of Muc-1 mucin expression in the mouse uterus during the estrus cycle, early pregnancy and placentation". Journal of Cell Science 105, n.º 2 (1 de junio de 1993): 397–405. http://dx.doi.org/10.1242/jcs.105.2.397.
Texto completoBrugger, Wolfram, Hans-Jörg Bühring, Frank Grünebach, Wichard Vogel, Sepp Kaul, Robert Müller, Tim H. Brümmendorf et al. "Expression of MUC-1 Epitopes on Normal Bone Marrow: Implications for the Detection of Micrometastatic Tumor Cells". Journal of Clinical Oncology 17, n.º 5 (mayo de 1999): 1535. http://dx.doi.org/10.1200/jco.1999.17.5.1535.
Texto completoSchmitt, Fernando C., Mónica B. Pereira y Celso A. Reis. "MUC 5 expression in breast carcinomas". Human Pathology 30, n.º 10 (octubre de 1999): 1270–71. http://dx.doi.org/10.1016/s0046-8177(99)90052-7.
Texto completoTesis sobre el tema "Muc expression"
BORTESI, Laura. "Muc expression and their prognostic value in cholangiocarcinoma". Doctoral thesis, Università degli Studi di Verona, 2009. http://hdl.handle.net/11562/337443.
Texto completoCholangiocarcinoma (CC) is a malignant tumour composed of cells resembling those of the bile ducts and the second most common primary hepatic tumor after hepatocellular carcinoma, comprising 5-10% of primary liver neoplasms. Worldwide, cholangiocarcinoma accounts for 3% of all gastrointestinal cancers. Several studies have shown that the incidence and mortality rates of intrahepatic CC (IHCC) are rising, and those of extrahepatic cholangiocarcinoma (EHCC) are declining worldwide. To date, radical surgery is the only therapy offering a potential cure for CC patients, whose prognosis is generally poor with survival limited to few months. At present, the lack of a sensitive and specific early diagnostic marker is one of the reasons why CC has a fairly late presentation. Our aim was to find out a sensitive and specific marker which could be detected in patient serum and be correlated with tumor type and tumor burden since the potential survival benefit from early detection is shown by 70-80% survival for patients with early cholangiocarcinoma that was discovered incidentally on transplantation for primary sclerosing cholangitis. Mucins are heavily glycosylated glycoproteins and play a protective role in cells, in part serving as a barrier to the epithelial surface and to tumor cells. Boonla C. et al. recently showed that MUC5AC mucin is present in significant concentrations in serum from patients with CC. In a recent report, MUC5AC significantly correlated with neural invasion and advanced CC stage. Only a few studies have been carried out about mucins expression, in particular the gastric type and their relationship with CC morphology and prognosis. We stained all tissue for MUC1, MUC2, MUC6 and MUC5AC. The only interesting results were with MUC5AC. Recently the Liver Cancer Study Group of Japan divided IHCC into three morphological types: mass-forming (MF), periductal infiltrating (PI) and intraductal growth (IG). MF type is characterized by the presence of a spherical mass with a distinct border in the liver parenchyma, PI type presents tumor infiltration along the bile duct, occasionally involving the surrounding blood vessels and/or hepatic parenchyma, IG is characterized by papillary and/or granular growth into the bile duct lumen. PI type of CC present a significantly higher frequency of perineural invasion, lymph node metastasis and extrahepatic recurrence than MF type. The 5-year survival rates of patients with IG tumors or MF tumors is significantly better than those of patients with MF plus PI tumors or PI type alone. There is increasing evidence that intrahepatic cholangiocarcinoma should be divided in peripheral CC and perihilar CC based on etiopathogenesis, biological behaviour and clinical features. Perihilar CC may evolve from the lining epithelia of the major branches of the right and left hepatic bile duct and also from peribiliary glands around them and histologically is an adenocarcinoma resembling many of the features of hilar or extrahepatic CC. Peripheral CC presumably develop from small bile duct, ductules or canals of Hering. Hepatic progenitor cell may be involved in the tumorigenesis of peripheral CC. Distinguishing perihilar from hilar CC is often difficult, especially in advanced cases. In this study together with the surgeons we propose a different classification: peripheral CC for tumors that growth inside the liver parenchima, perihilar for tumors located in the liver but involving the hilum and for Klatskin tumors and extrahepatic for tumors of the distal biliary tract. This classification correlates well with morphology. Most (30/35) peripheral CC are of the MF type with only 5 cases MF+PI. Perihilar CC and EHCC are mostly PI or MF+PI reflecting a different growth pattern between the two. Beside a different growth pattern there is a statistical difference between the tumor types when comparing MUC5AC expression. 30 out of 35 (85,7%) peripheral CC were MUC5AC negative. 26 out of 39 (66,6%) perihilar CC were MUC5AC positive with different intensities but positive. 13 cases were negative. Of these 13 cases in 8 cases there were same positive cells but not enough to reach 5% of the total (our cut-off value), we don’t know if this positivity is of any significance, but it is something different compared to the true negativity that we see in MF. In our study MUC5AC seems to be a good immunohistochemical marker that can distinguish peripheral from perihilar CC, that correlates well with morphology and has a prognostic significance as well. This marker can be measured in the serum and can be used in the panel of tumor markers to search for in CC and could be useful in the follow-up.
Bedei, Ivonne. "Untersuchung zur MUC-18-Expression des metastasierenden malignen Melanoms mittels der RT-PCR-Methode". Ulm : Universität Ulm, Medizinische Fakultät, 2001. http://www.bsz-bw.de/cgi-bin/xvms.cgi?SWB9818607.
Texto completoBrandenburg, Anna Klara. "Untersuchungen zur Expression der MUC1/Y und MUC/Z-Spleissvarianten des Tumorantigens MUC1 in Normalgeweben und Karzinomen des Magens sowie des ösophagogastrischen Überganges /". Köln, 2008. http://opac.nebis.ch/cgi-bin/showAbstract.pl?sys=000253343.
Texto completoBedei, Ivonne [Verfasser]. "Untersuchung zur MUC-18-Expression des metastasierenden malignen Melanoms mittels der RT-PCR-Methode / Ivonne Bedei". Ulm : Universität Ulm. Medizinische Fakultät, 2002. http://d-nb.info/1015323618/34.
Texto completoLlupi, Matilda y Rabije Qoku. "Expression of mucins in normal salivary glands and mucoepidermoid carcinoma of salivary glands". Thesis, Malmö högskola, Odontologiska fakulteten (OD), 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:mau:diva-19760.
Texto completoMucoepidermoid carcinomas (MECs) are malignant epithelial mucin-producing tumours encountered in both major and minor salivary glands. The aim of this study was to investigate the histological characteristics of the expression of mucins (MUC1, MUC4, MUC5AC, MUC5B, MUC6) in MECs in search for a possible correlation between qualitative mucin expression and tumour grade. Twelve low-grade, five high-grade MECs and nine normal salivary glands adjacent to tumour tissue were investigated for these mucins by immunohistochemistry. The samples were evaluated with respect to staining pattern and positivity of specific cell types. Normal acinar cells mainly expressed the cytoplasmic mucin MUC5B. MUC1 and MUC4 were expressed in normal ductal cells in approximately half of the samples whereas MUC5AC expression was rare in normal salivary glands. MECs expressed MUC1, MUC4, MUC5AC and MUC5B. The apical membrane of mucous cells lining the cystic cavities showed the strongest staining for MUC1 and MUC4. The expression of MUC4 in mucous cells decreased with increasing histological grade. Expression of salivary mucin MUC5B in mucous cells in low-grade MECs was less intense compared to the expression of MUC5AC in the same cells. In high-grade tumours, a higher expression of MUC5B compared to MUC5AC was noted. In conclusion, MECs express different mucin quantity compared to normal salivary glands. MUC5AC expression in salivary tumour tissue seems to be a metaplastic feature and MUC4 appears to be related to tumour differentiation grade. The relationship between MUC5AC and MUC5B expression could be a useful tool in the diagnosis and estimation of prognosis of MECs.
Vogel, Teresa Maria [Verfasser]. "Die Expression von MHC Klasse I verwandten Genen (MIC) bei Psoriasis vulgaris / Teresa Maria Vogel". Kiel : Universitätsbibliothek Kiel, 2018. http://d-nb.info/1156264642/34.
Texto completoCarminati, Patricia de Oliveira. "Respostas celulares aos danos causados pelo antitumoral cisplatina em linhagens de fibroblastos humanos normais (MRC-5) e astrocítica (U343 MG-a)". Universidade de São Paulo, 2005. http://www.teses.usp.br/teses/disponiveis/17/17135/tde-21082007-103139/.
Texto completoA variety of antitumoral agents is capable of inducing DNA damage and eliciting cell cycle arrest, DNA repair or apoptotic responses. The initial response is a cell cycle arrest in an attempt to repair the DNA damage, but under conditions of extensive DNA lesions and high drug cytotoxicity, a signaling cascade triggers alternative mechanisms that inhibit cell proliferation and activate cell death pathways. Astrocytomas are the most common neoplasm of the central nervous system, comprising more than 60% of primary brain tumors. The standard treatment for theses tumors are radiotherapy followed by chemotherapy, however, the prognostic for these patients is still very discouraging. Cisplatin is an efficient DNA-damaging antitumor agent employed for the treatment of various human cancers, including gliomas. This drug binds to DNA, producing diverse types of adducts, which can block replication, transcription, and lead to apoptosis induction. In the present work, we analyzed cellular responses to treatments with the anticancer agent cisplatin in MRC-5 (normal human fibroblasts SV40 transformed) and U343 MG-a (glioma cell line). The responses were evaluated in terms of cell survival, apoptosis induction and profiles of gene expression by the cDNA microarrays method (only for U343 cell line). Cisplatin treatment resulted in a pronounced reduction in MRC-5 cell survival (~ 1%) and U343 (< 1%) after five days of treatment (cell survival test) with several concentrations of cisplatin, ranging from 12.5 to 300 ?M. Following 24h of treatment under similar cisplatin concentrations the survival was reduced at about 20-80% (cytotoxicity test). Both cell lines underwent apoptosis after treatment with different concentrations of cisplatin (12.5; 25 and 50 ?M), but U343 cells presented a maximal frequency of 20.4% apoptosis (25 ?M cisplatin treatment for 72h), while MRC-5 cells presented 11.0% (50 ?M cisplatin treatment for 48h). Analysis of gene expression performed for U343 cells treated with 25 ?M cisplatin for 48h showed several genes that were found significantly (p ? 0,05) down-regulated, most of them related with cytoskeleton alterations (TBCD, RHOA, LIMK2 and MARK1), apoptosis or cell survival (BCL2-XL, ING1, RHOA, VDP, TIMP2, DYRK3 and NFKBIE), cell invasion or metastasis (LIMK2, TIMP2 and CALU), DNA repair (SMC1L1), and cell metabolism (DYRK3, MARK1, TBCD, LIMK2, VDP and P4HB), among others. As a whole, these data demonstrate a serious commitment of the cell machinery after cisplatin-induced cellular damage. About 20% of the cell death corresponds to apoptosis, as was showed by the present assays. However, most of the cells are eliminated by the action of the drug in various levels of the metabolism and maintenance of cell integrity, due to the elevated degree of cisplatin citotoxicity, as demonstrated in cell survival tests.
Berggren, Bremdal Karin. "Evolution of MHC Genes and MHC Gene Expression". Doctoral thesis, Uppsala universitet, Evolutionsbiologi, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-122011.
Texto completoSandoval, Evandra Strazza Rodrigues. "Avaliação do efeito imunomodulador das células mesenquimais estromais humanas em linfócitos T infectados pelo HTLV-1". Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/60/60135/tde-18122014-163958/.
Texto completoThe characteristics of human multipotent mesenchymal stromal cells (MSC) can be influenced by the inflammatory microenvironment. However, the activity of the MSC against viral infections and the exact contribution of the infection to MSC dysfunction remain to be elucidated. We evaluated the immunosuppressive effect of MSC on HTLV-1 infected T lymphocytes and the susceptibility of MSC for this retroviral infection. Assays using co-culture of MSC and HTLV-1+ T lymphocyte lineages resulted in a decrease of tax gene expression and HTLV-1 p19 antigen. The reduction of the tax gene expression and the HTLV-1 p19 were associated with increased IL-6 secretion and higher PGE2, IDO and VCAM-1 gene expression. To confirm if MSC immunoregulation can influence the proliferation of HTLV-1 infected T lymphocytes, we compared the proliferation of HTLV-1+ individuals and healthy individuals cultured in the presence of MSC. It was observed that the lymphoproliferative inhibition by MSC in infected lymphocytes was similar to the control cells, and this effect was mediated by the expression of IDO and PGE2 genes. Furthermore, the pol gene and the HTLV-1 p19 protein were less expressed after co-culture assay with MSC, suggesting that the immunoregulation by MSC is effective in HTLV-1 infected T cells. In order to investigate the changes caused by HTLV-1 in MSC, we performed morphological and ultrastructural analysis of MSC exposed to HTLV-1 in vitro. The contact with HTLV-1 induced an increase of the intracellular vesicles, in addition the MSC cell surface molecules VCAM-1, ICAM-1 and HLA-DR were upregulated. The expression levels of VCAM-1 and HLA-DR molecules were increased in MSC cultured in the presence of PBMC isolated from HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) individuals. The MSC differentiation process into osteocytes and adipocytes was not impaired by HTLV-1. In addition, MSCs were efficiently infected by HTLV-1 in vitro due to the direct contact with the HTLV-1-infected cells. However, cell-free virus particles were not capable of causing productive infection. Finally, to ensure the biological function of MSC in HTLV-1 infected patients, we investigated bone marrow (BM) cells from HTLV-1 asymptomatic carriers (HAC) and HAM/TSP individuals. Initially, we observed an infiltration of CD4+ T-cell lymphocytes in BM from HTLV-1 infected individuals and the detection of provirus revealed HTLV-1 integration. The number of colonies of fibroblast progenitor cells (CFU-F) was lower in HTLV-1 infected individuals compared to control. HTLV-1 MSC isolated showed surface molecules expression and differentiation into adipogenic and osteogenic cells similar to control MSC. Proviral DNA and HTLV-1 p19 protein were detected in MSC from HTLV-1 patients. The comparison of global gene expression profiles between MSC isolated from HAM/TSP and HAC individuals revealed that cathepsin B and ribosomal protein L10 were differentially expressed. In conclusion, this study suggests the importance of MSC immunomodulation on HTLV-1 infected T lymphocytes and describe that HTLV-1 infects and alters the biological characteristics of MSC.
Loh, Andrew Xiong Wan. "Cis-acting polymprophism of MIC game expression". Thesis, University College London (University of London), 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.497874.
Texto completoLibros sobre el tema "Muc expression"
Hey, Neil Anthony. MUC1 expression in human endometrium. Manchester: University of Manchester, 1996.
Buscar texto completoUrban, Robert G. y Roman M. Chicz. MHC Molecules: Expression, Assembly and Function. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4684-6462-7.
Texto completo1962-, Urban Robert G. y Chicz Roman M, eds. MHC molecules: Expression, assembly, and function. New York: Chapman & Hall, 1996.
Buscar texto completoEric, Blair G., Pringle Craig R y Maudsley D. John, eds. Modulation of MHC antigen expression and disease. Cambridge: Cambridge University Press, 1995.
Buscar texto completoJaffe, Leah. Regulation of MHC Class I gene expression during mouse embryogenesis. [New York]: Columbia University, 1992.
Buscar texto completoTello, Carlos Alberto Barron. Transkription des Bakteriophagen Mu. Konstanz: Hartung-Gorre, 1986.
Buscar texto completoBoeckh, Clemens. Expression der frühen Funktionen des mutagenen E.coli-Bakteriophagen Mu und ihre Wirkung auf die Wirtszellen. Konstanz: Hartung-Gorre, 1986.
Buscar texto completoWiner, Shawn. Peptide dose, MHC affinity, and target self-antigen expression are critical for effective immunotherapy of nonobese diabetic mouse prediabetes. Ottawa: National Library of Canada, 2001.
Buscar texto completoCho, Chae-hyŏn. Chungganyŏp chulgi sep'o ŭi tonggyŏl pangbŏp kaebal mit yujŏnhakchŏk punsŏk e kwanhan yŏn'gu =: Development of cryopreservation and gene expression analysis in porcine mesenchyamal stem cell (MSC). [Seoul]: Nongch'on Chinhŭngch'ŏng, 2008.
Buscar texto completo(filólogo), Brown Martin, ed. ¡No me des calabazas!: Equivalencias en inglés de expresiones cotidianas-- ¡y mucho más! ; Don't give me the cold shoulder! : literal (amusing) and colloquial (useful) translations of everyday expressions-- and so much more! [Madrid]: A. Arienza, 2010.
Buscar texto completoCapítulos de libros sobre el tema "Muc expression"
Malik, Waqar. "Expressions". En Learn Swift on the Mac, 157–64. Berkeley, CA: Apress, 2015. http://dx.doi.org/10.1007/978-1-4842-0376-7_17.
Texto completoMalik, Waqar. "Expressions". En Learn Swift 2 on the Mac, 49–58. Berkeley, CA: Apress, 2015. http://dx.doi.org/10.1007/978-1-4842-1627-9_5.
Texto completoMalissen, B. y R. N. Germain. "Workshop Summary: Transfection of MHC Genes". En Regulation of Immune Gene Expression, 341–45. Totowa, NJ: Humana Press, 1986. http://dx.doi.org/10.1007/978-1-4612-5014-2_33.
Texto completoChicz, Roman M. y Robert G. Urban. "Major Histocompatibility Antigens: An Introduction". En MHC Molecules: Expression, Assembly and Function, 1–8. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4684-6462-7_1.
Texto completoParker, Kenneth C. "Epitope Prediction Algorithms for Class I MHC Molecules". En MHC Molecules: Expression, Assembly and Function, 163–80. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4684-6462-7_10.
Texto completoJameson, Stephen C. y Kristin A. Hogquist. "Options for TCR Interactions: TCR Agonists, Antagonists and Partial Agonists". En MHC Molecules: Expression, Assembly and Function, 181–90. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4684-6462-7_11.
Texto completoTsomides, Theodore J. "Role of Ligand Density in T Cell Reactions". En MHC Molecules: Expression, Assembly and Function, 191–206. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4684-6462-7_12.
Texto completoVignali, Dario A. A. "Cooperative Recognition of MHC Class II:Peptide Complexes by the T Cell Receptor and CD4". En MHC Molecules: Expression, Assembly and Function, 207–28. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4684-6462-7_13.
Texto completoColonna, Marco. "Receptors for MHC Class I Molecules in Human Natural Killer Cells". En MHC Molecules: Expression, Assembly and Function, 229–41. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4684-6462-7_14.
Texto completoDavenport, Miles P. y Adrian V. S. Hill. "The MHC in Host-Pathogen Evolution". En MHC Molecules: Expression, Assembly and Function, 243–60. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4684-6462-7_15.
Texto completoActas de conferencias sobre el tema "Muc expression"
Lee, Myung H. "Zernike decomposition of the thermal blooming-induced phase variation for a Gaussian beam". En OSA Annual Meeting. Washington, D.C.: Optica Publishing Group, 1990. http://dx.doi.org/10.1364/oam.1990.mu4.
Texto completoUplinger, W. G. "Relative optical mass in a nonisothermal atmosphere". En OSA Annual Meeting. Washington, D.C.: Optica Publishing Group, 1988. http://dx.doi.org/10.1364/oam.1988.ww4.
Texto completoYarrison-Rice, Jan M., Gregory J. Salamo, William W. Clark, Edward J. Sharp, Gary L. Wood y Ratnakar R. Neurgaonkar. "Measurements of photorefractive response times with low-irradiance picosecond and cw light sources". En OSA Annual Meeting. Washington, D.C.: Optica Publishing Group, 1991. http://dx.doi.org/10.1364/oam.1991.mu2.
Texto completoLi, Hanting, Mingzhe Sui, Zhaoqing Zhu y Feng Zhao. "MMNet: Muscle Motion-Guided Network for Micro-Expression Recognition". En Thirty-First International Joint Conference on Artificial Intelligence {IJCAI-22}. California: International Joint Conferences on Artificial Intelligence Organization, 2022. http://dx.doi.org/10.24963/ijcai.2022/150.
Texto completoBan, Kyeong-jin, Jong-chan Kim y Eung-kon Kim. "An Object Expression System using Depth-maps". En 2011 IEEE/FTRA International Conference on Multimedia and Ubiquitous Engineering (MUE). IEEE, 2011. http://dx.doi.org/10.1109/mue.2011.18.
Texto completoYano, Tomoki, Kouyou Otsu y Tomoko Izumi. "Verification of the Effects of Personalized Evacuation Alerts using Behavioral or Location Information with the Sense of Urgency in a Disaster". En 13th International Conference on Applied Human Factors and Ergonomics (AHFE 2022). AHFE International, 2022. http://dx.doi.org/10.54941/ahfe1001701.
Texto completoWesthoven, Martin, Tim van der Grinten y Steffen Mueller. "Perceptions of a Help-Requesting Robot - Effects of Eye-Expressions, Colored Lights and Politeness of Speech". En MuC'19: Mensch-und-Computer. New York, NY, USA: ACM, 2019. http://dx.doi.org/10.1145/3340764.3340783.
Texto completoXia, Fang y Lv Hong. "Research on algorithm recognition based on characteristic expression". En 2011 International Conference on Mechatronic Science, Electric Engineering and Computer (MEC). IEEE, 2011. http://dx.doi.org/10.1109/mec.2011.6025995.
Texto completoYang, Haisu, Rosalba Tamayo, Bruce Horten, Moacyr DaSilva, Maryann Gangi, Evelyn Vazquez, Daisy Joseph, Patricia Okamoto y Thomas Scholl. "Abstract LB-274: Clinical significance of MUC1, MUC2 and CK17 expression patterns in the diagnosis of pancreatic carcinoma". En Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-lb-274.
Texto completoMiedler, J., F. Abdul-Karim, N. Wang y J. Baar. "MUC1 expression in early-stage triple-negative breast cancer." En CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-3009.
Texto completoInformes sobre el tema "Muc expression"
Carson, Daniel D. Mucin (MUC1) Expression and Function in Prostate Cancer Cells. Fort Belvoir, VA: Defense Technical Information Center, marzo de 2004. http://dx.doi.org/10.21236/ada432401.
Texto completoCoticchia, Christine M. y Robert B. Dickson. Fas/FasL System in c-Myc Expressing Mammary Carcinoma Cells. Fort Belvoir, VA: Defense Technical Information Center, junio de 2002. http://dx.doi.org/10.21236/ada411302.
Texto completoCoticchia, Christine M. y Robert B. Dickson. Fas/FasL System in c-Myc Expressing Mammary Carcinoma Cells. Fort Belvoir, VA: Defense Technical Information Center, junio de 2003. http://dx.doi.org/10.21236/ada422986.
Texto completoDickson, Robert B. Modulation of Cyclin Expression by C-MYC in Malignant and Nonmalignant Mammary Epithelial Cells. Fort Belvoir, VA: Defense Technical Information Center, septiembre de 1995. http://dx.doi.org/10.21236/ada302398.
Texto completoPopov, Todor M., Gergana S. Stancheva, Silva G. Giragosyan, Orlin V. Stoyanov, Sylvia E. Valcheva, Emil I. Tsenev, Radka P. Kaneva y Diana P. Popova. Correlations between PKM2, HIF‑1α, c‑Myc and p53 mRNA Expression Levels in Laryngeal Carcinoma. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, mayo de 2018. http://dx.doi.org/10.7546/crabs.2018.05.14.
Texto completoEl Bejjani, Rachid M. Effect of MUC1 Expression on EGFR Endocytosis and Degradation in Human Breast Cancer Cell Lines. Fort Belvoir, VA: Defense Technical Information Center, abril de 2009. http://dx.doi.org/10.21236/ada504024.
Texto completoEl Bejjani, Rachid M. Effect of MUC1 Expression on EGFR Endocytosis and Degradation in Human Breast Cancer Cell Lines. Fort Belvoir, VA: Defense Technical Information Center, abril de 2007. http://dx.doi.org/10.21236/ada470580.
Texto completoLin, Charles. Understanding Selective Downregulation of c-Myc Expression through Inhibition of General Transcription Regulators in Multiple Myeloma. Fort Belvoir, VA: Defense Technical Information Center, junio de 2014. http://dx.doi.org/10.21236/ada605044.
Texto completoLin, Charles. Understanding Selective Downregulation of c-Myc Expression through Inhibition of General Transcription Regulators in Multiple Myeloma. Fort Belvoir, VA: Defense Technical Information Center, junio de 2015. http://dx.doi.org/10.21236/ada620612.
Texto completoMcGuffie, Eileen M. y Carlo V. Catapano. Development of Triplex-Forming Oligonucleotides to Inhibit Expression of the c-myc Oncogene in Breast Cancer Cells. Fort Belvoir, VA: Defense Technical Information Center, abril de 2003. http://dx.doi.org/10.21236/ada416148.
Texto completo